C
Charles M. Perou
Researcher at University of North Carolina at Chapel Hill
Publications - 645
Citations - 235604
Charles M. Perou is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 156, co-authored 573 publications receiving 202951 citations. Previous affiliations of Charles M. Perou include North Carolina Central University & University of Chicago.
Papers
More filters
Journal ArticleDOI
Association of a compact 13-gene VEGF signature with OS in E2100.
Scooter Willis,Kathy D. Miller,Brandon F Young,Charles M. Perou,Zhiyuan Hu,Joseph A. Sparano,Robert Gray,George W. Sledge,Nancy E. Davidson,Brian Leyland-Jones +9 more
TL;DR: On 18 Nov, 2011, the FDA Commissioner revoked the agency’s approval of bevacizumab for the breast cancer indication because of the lack of evidence of an improvement in overall survival or a clinical benefit to patients sufficient to outweigh the risks.
Journal ArticleDOI
Identification of drug targets for the treatment of Basal-like tumors
TL;DR: Primary breast tumor gene expression data and cell line models were used to identify and validate candidate biologically-based therapies for Basal-like tumors and suggest that inhibition of SQLE activity can reduce cell line proliferation rates and, in some instances, was synergistic with chemotherapy.
Journal ArticleDOI
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer
Aleix Prat,Fara Brasó-Maristany,Olga Martínez-Sáez,Esther Sanfeliu,Youli Xia,Meritxell Bellet,Patricia Galván,D. Martinez,Tomás Pascual,Mercedes Marín-Aguilera,A. Rodríguez,Nuria Chic,Barbara Adamo,Laia Paré,Maria Vidal,Mireia Margeli,Ester Ballana,Marina Gómez-Rey,Mafalda Melo Oliveira,E. Felip,Judit Matito,Rodrigo Sánchez-Bayona,Anna Suñol,Cristina Saura,Eva Ciruelos,P. Tolosa,Montserrat Muñoz,Blanca Gonzalez-Farre,Patricia Villagrasa,Joel S. Parker,Charles M. Perou,Ana Vivancos +31 more
TL;DR: In this article , the authors performed 0.5X shallow whole-genome sequencing in plasma from 459 patients with metastatic breast cancer, including 245 patients treated with endocrine therapy and a CDK4/6 inhibitor (ET + CDK 4/6i) from 2 independent cohorts.
Journal ArticleDOI
Reply to Y. Yamamoto et al
Book ChapterDOI
Functional Genomics for Identifying Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention
TL;DR: A model for using genomic profiling to identify targets for chemoprevention in Phase II trials is presented and the basic methodology described here for breast lesions could also be applied to other tissues to identify tissuespecific risk and response biomarkers.